2-dodecan-6-yl-1H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-dodecan-6-yl-1H-imidazole
• 化学式: C₁₅H₂₈N₂
• 分子量: 236.4
• InChiKey: QZFSHQFVAVIHCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• COMPOUNDS AND METHODS OF PREPARING COMPOUNDS S1P1 MODULATORS
  申请人：Trevena, Inc.

  公开号：US20210147402A1

  公开（公告）日：2021-05-20

  The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.

  本实施例部分涉及可用于制备化合物I的过程和组合物，或其药用可接受的盐。
• Bromodomain inhibitors
  申请人：Celgene Quanticel Research, Inc.

  公开号：US10023592B2

  公开（公告）日：2018-07-17

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

  本发明涉及取代的杂环衍生物化合物、包含所述化合物的组合物，以及所述化合物和组合物通过抑制溴域介导的对组蛋白等蛋白质乙酰赖氨酸区的识别而用于表观遗传调控的用途。所述组合物和方法可用于治疗癌症和肿瘤性疾病。
• BROMODOMAIN INHIBITORS
  申请人：Celgene Quanticel Research, Inc.

  公开号：US20170158709A1

  公开（公告）日：2017-06-08

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.